logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11497796 B1

PDFFull Text
Date of Patent:
Nov. 15, 2022

Filed:

Feb. 15, 2019

Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in methods of treatment

Applicant:

University Health Network, Toronto, CA;

Inventors:

Philippe P. Monnier, Toronto, CA;

Nardos G. Tassew, Toronto, CA;

Assignee:

UNIVERSITY HEALTH NETWORK, Toronto, CA;

Attorneys:

Casimir Jones SC

Lisa Mueller

Primary Examiner:

Aurora M Fontainhas

Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 49/00 (2006.01); C07K 14/47 (2006.01); A61K 39/395 (2006.01); A61P 25/14 (2006.01); A61P 21/00 (2006.01); A61P 25/28 (2006.01); A61K 38/44 (2006.01); A61K 31/137 (2006.01); C07K 16/28 (2006.01); A61K 31/724 (2006.01); A61K 31/365 (2006.01); A61K 31/7048 (2006.01); A61K 38/48 (2006.01); C07K 14/435 (2006.01); C07K 14/705 (2006.01); G01N 33/53 (2006.01); A61K 31/495 (2006.01); G01N 33/50 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/443 (2013.01); A61K 31/137 (2013.01); A61K 31/365 (2013.01); A61K 31/495 (2013.01); A61K 31/7048 (2013.01); A61K 31/724 (2013.01); A61K 38/177 (2013.01); A61K 38/482 (2013.01); C07K 14/435 (2013.01); C07K 14/705 (2013.01); C07K 16/28 (2013.01); C12Y 101/03006 (2013.01); G01N 33/5058 (2013.01); G01N 33/53 (2013.01); A61K 2039/505 (2013.01); C07K 2317/30 (2013.01); C07K 2317/76 (2013.01); G01N 2333/4703 (2013.01);
Abstract

Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.

Find Patent Forward Citations

Loading…